WASHINGTON, D.C. – August 8, 2018 – The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2018.
By further curating information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from more than 875 cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events and current legislative and regulatory priorities.
The Q2 2018 data report also features commentary from ARM’s recent webinar on the RMAT designation, cohosted with Informa. The commentary includes insights from Michael Werner, ARM co-Founder and Senior Policy Counsel; Kevin Healy, Global Regulatory Lead at Roivant Sciences, representing Enzyvant Therapeutics; Gil Van Bokkelen, CEO of Athersys; and Tim Miller, President and Chief Scientific Officer at Abeona Therapeutics. The report also includes a brief comparison of the RMAT designation and the Breakthrough Therapy designation, provided by Amanda Micklus, Principal Analyst at Pharma Intelligence at Informa.
“There has been a tremendous amount of forward momentum during the first half of this year, both clinically and commercially,” said Janet Lynch Lambert, ARM’s Chief Executive Officer. “We’re excited for the continued growth of the regenerative medicine sector, and what it means for patients worldwide.”
Highlighted findings from the Q2 2018 data report include:
ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events.
About The Alliance for Regenerative Medicine